Search Results

Paratek Pharmaceuticals is betting that OptiNose’s chronic rhinosinusitis treatment will be a partner to its antibiotic treatment Nuzyra.

Paratek Pharmaceuticals, Inc. announced two key executive team promotions.

Paratek Pharmaceuticals, Inc. today announced that three new pre-clinical studies with NUZYRA ® (omadacycline) will be presented at European Society of Clinical Microbiology & Infectious Diseases Global (ESCMID Global, formerly ECCMID).

Paratek Pharmaceuticals, Inc. today announced that China’s National Healthcare Security Administration (NHSA) has added the oral formulation of NUZYRA® (omadacycline) to the country’s National Reimbursement Drug List (NRDL) for treatment of community-acquired bacterial pneumonia.

Paratek Pharmaceuticals, Inc. today announces that new data from NUZYRA ® (omadacycline) scientific and investigator-initiated research programs will be presented at IDWeek 2023.

Gurnet Point Capital and Novo Holdings A/S announced the completion of their acquisition of Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats.

Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing innovative medical therapies that create positive patient stories in the hospital, community and public health settings, announced positive top-line efficacy data for NUZYRA® as post-exposure prophylaxis in a non-human primate model of inhalational anthrax.